NBIX - Neurocrine Biosciences Inc logo

NBIX

Neurocrine Biosciences Inc

Neurocrine Biosciences develops and commercializes pharmaceuticals targeting neurological, psychiatric, endocrine, and immunological disorders. Key products include INGREZZA for tardive dyskinesia, Orilissa for endometriosis, and treatments for various movement disorders.

⚕️ Healthcare NASDAQ Listed 1996 $ USD
$1,000 invested 30 years ago$17,513today

Score Overview

1 Year
Score9.1
Net Growth39.70%
Net TrendGrew
Net Income Consistency
Rev Growth8.46%
Rev TrendGrew
Revenue Consistency
5 Years
Score9.4
Net Growth6x
Net TrendEvery year
Net Income Consistency
Rev Growth173.70%
Rev TrendEvery year
Revenue Consistency
10 Years
Score6.8
Net Growth5x
Net Trend80%
Net Income ConsistencyInconsistent
Rev Growth205x
Rev TrendEvery year
Revenue Consistency89%
20 Years
Score4.8
Net Growth7x
Net Trend60%
Net Income ConsistencyInconsistent
Rev Growth78x
Rev Trend70%
Revenue ConsistencyInconsistent
30 Years
Score4.6
Net Growth112x
Net Trend50%
Net Income ConsistencyInconsistent
Rev Growth160x
Rev Trend63%
Revenue ConsistencyInconsistent
All Time
Score4.6
Net Growth112x
Net Trend50%
Net Income ConsistencyInconsistent
Rev Growth160x
Rev Trend63%
Revenue ConsistencyInconsistent

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-06-25
$ 164.18
1 Year2025-06-25
$ 127.7828.49%
5 Years2021-06-25
$ 100.2963.71%
10 Years2016-06-24
$ 43.28279.34%
20 Years2006-06-23
$ 9.8516x
30 Years1996-06-25
$ 9.3817x
All Time1996-05-23
$ 12.5013x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 3.10B$ 668M$ 1.31B
2025$ 2.86B$ 478M$ 1.48B
2024$ 2.35B$ 341M$ 1.07B
2023$ 1.88B$ 249M$ 1.03B
2022$ 1.48B$ 154M$ 989M
2021$ 1.13B$ 89M$ 711M
2020$ 1.04B$ 407M$ 801M
2019$ 788M$ 37M$ 670M
2018$ 451M$ 21M$ 650M
2017$ 161M-$ 142M$ 515M
2016$ 15M-$ 141M$ 307M
2015$ 19M-$ 88M$ 379M
2014$ 0.00-$ 60M$ 193M
2013$ 2M-$ 46M$ 145M
2012$ 53M$ 5M$ 173M
2011$ 77M$ 37M$ 129M
2010$ 33M-$ 7M$ 126M
2009$ 2M-$ 51M$ 53M
2008$ 3M-$ 88M$ 80M
2007$ 1M-$ 207M$ 179M
2006$ 39M-$ 107M$ 182M
2005$ 123M-$ 22M$ 273M
2004$ 85M-$ 45M$ 301M
2003$ 139M-$ 30M$ 453M
2002$ 18M-$ 94M$ 244M
2001$ 41M-$ 36M$ 319M
2000$ 14M-$ 28M$ 164M
1999$ 16M-$ 16M$ 91M
1998$ 16M-$ 20M$ 11M
1997$ 26M$ 5M$ 15M
IPO1996$ 19M$ 5M$ 11M